Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up. FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels. INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions. FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 4×
“The basic pillars of the McDonald criteria are identi fi cation of CNS lesions, using surrogate markers, and their dissemination in time (DIT) and space (DIS).”
InfluentialSelf-citationNeurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 2×
“…fl uid (CSF) and to a lesser extent into the peripheral blood, where they can be measured by highly sensitive single molecule assays (SiMoA) [5]. sNfL has been shown to correlate with brain and spinal cord atrophy, as well as clinical relapses, T2 lesion load, and gadolinium-enhancing (Gd+)…”
Bayesian estimation supersedes the t-test
Kruschke, J. K. (2013) · Journal of Experimental Psychology: General · doi:10.1037/a0029146 · Cited by 1,530 · cited 1×
“This analysis provides complete distribution of credible values for group means and their differences [25].”
Barkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251 · cited 1×
“At baseline and year two, patients with (cid:2) 9 cranial T2 lesions according to Barkhof criteria [27] had signi fi cantly higher sNfL levels (baseline: 13.0 pg/ml, IQR 8.2 (cid:1) 23.5 pg/ml, n = 567; two year follow-up: 8.4 pg/ ml, 6.1 (cid:1) 12.2 pg/ml, n = 573) than those with 1-8 T2 lesions…”
InfluentialSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164 · cited 2×
“…diagnosis of patients, sNFL might also serve as a marker of treatment response, as sNFL levels have been described to decrease after initiation of any DMT [8,10,20] and speci fi cally after switch from injectable therapies to fi ngolimod [20] or after initiation of interferon-beta-treatment [31].”
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 1×
“Neurofilament proteins are part of the neuronal cytoskeleton and are elevated in various neurological diseases associated with neuronal damage including neurodegenerative diseases [6] and stroke [7], as well as MS [8].”
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Filippi, M., Rocca, M. A., Ciccarelli, O., De Stefano, N., Evangelou, N., Kappos, L., Rovira, A., Sastre-Garriga, J., Tintorè, M., Frederiksen, J. L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00393-2 · Cited by 880 · cited 1×
“The definition of DIT has changed markedly in the current 2017 McDonald revision by additionally including a) symptomatic Gd+ lesions [15] and b) the presence of oligoclonal bands (OCB) in the CSF as a substitute for clinical or imaging evidence of DIT.”
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517 · cited 1×
“Since the range of sNfL concentrations in serum is smaller than in CSF, some samples with a sample CV above 20% (or missing replicate result) were measured twice, as in previous publications [8,9].”
Cantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2137 · Cited by 199
Cited by
Benkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00009-6 · Cited by 628
Self-citationJakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Self-citationBenkert, P., Meier, S., Schaedelin, S. A., Manouchehrinia, A., Yaldizli, Ö., Maceski, A. M., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T. J., et al. (n.d.) · UCL Discovery (University College London) · doi:10.48350/165754 · Cited by 457
Self-citationNeurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
Self-citationBlood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296
Metadata
- Authors
- Bittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., Meuth, S. G., Bayas, A., Paul, F., Hartung, H.-P., Linker, R., Heesen, C., Stangel, M., Wildemann, B., Then Bergh, F., Tackenberg, B., Kuempfel, T., Weber, F., Zettl, U. K., Ziemann, U., Tumani, H., Groppa, S., Mühlau, M., Lukas, C., Hemmer, B., Wiendl, H., Gold, R., & Zipp, F.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 56
- Pages
- 102807
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W3028430208
- Cited by
- 128
- References
- 9
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. https://app.cochat.ai/papers/10.1016/j.ebiom.2020.102807
- The paper
- Bittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., Meuth, S. G., Bayas, A., Paul, F., Hartung, H.-P., Linker, R., Heesen, C., Stangel, M., Wildemann, B., Then Bergh, F., Tackenberg, B., . . . Zipp, F. (2020). Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine. https://doi.org/10.1016/j.ebiom.2020.102807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.